文献速递肿瘤 PET/CT

[68Ga]Ga-THP-APN09一种新型PD-L1靶向纳米抗体放射性示踪剂的临床前评估与初步临床研究:快速一步法放射性标记与PET显像

Preclinical evaluation and pilot clinical study of [68Ga]Ga-THP-APN09, a novel PD-L1 targeted nanobody radiotracer for rapid one-step radiolabeling and PET imaging.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-08-09

研究制备了新型68Ga标记纳米抗体[68Ga]Ga-THP-APN09,在室温下10分钟内完成一步法标记,放射化学产率>99%。在小鼠模型中,H1975和A549PD-L1肿瘤分别以8.3:1和2.2:1的比值清晰显像。9例可切除NSCLC患者的首次人体研究显示,示踪剂摄取主要在肾脏和脾脏,肿瘤摄取与PD-L1表达TPS正相关(rs=0.8763,P=0.019),MPR患者SUVmax高于非MPR患者(中位2.73 vs 2.10,P=0.036)。

要点

  • [68Ga]Ga-THP-APN09可在室温pH 6.0-6.5下10分钟完成标记,放射化学产率>99%,比活度13.9-27.8 GBq/μmol。
  • 小动物PET/CT中H1975和A549PD-L1肿瘤对PD-L1阴性A549的摄取比分别为8.3:1和2.2:1。
  • 9例NSCLC患者中肿瘤摄取与PD-L1表达TPS正相关(rs=0.8763,P=0.019),MPR患者SUVmax高于非MPR患者(中位2.73 vs 2.10,P=0.036)。

核心结论

  • [68Ga]Ga-THP-APN09有潜力转化为基于药盒的放射性示踪剂,用于快速、简单、一步法室温标记。
  • 该示踪剂可检测肿瘤PD-L1表达水平,并可能预测PD-1免疫联合化疗的疗效。
  • 原文指出需要在大数量病例中确认。

研究设计与样本

  • 临床前研究结合首次人体临床转化试验(NCT05156515,2021年12月12日注册)。
  • 临床前部分在A549、H1975和A549PD-L1三种肿瘤细胞及其荷瘤小鼠中进行细胞摄取、PET/CT显像和离体生物分布研究。
  • 临床部分纳入9例可切除NSCLC患者,评估安全性、辐射剂量学、生物分布及示踪剂摄取与免疫组化染色和主要病理缓解(MPR)的相关性。

主要发现

  • 放射合成在室温pH 6.0-6.5下10分钟完成,放射化学产率>99%,比活度13.9-27.8 GBq/μmol。
  • 细胞摄取研究反映的细胞表面PD-L1表达水平由流式细胞术观察为A549PD-L1 > H1975 > A549。
  • 小动物PET/CT中H1975和A549PD-L1肿瘤对PD-L1阴性A549肿瘤的摄取比分别为8.3:1和2.2:1。
  • 离体生物分布显示肿瘤摄取与PET结果一致,A549PD-L1摄取最高(8.20 ± 0.87%ID/g),其次H1975(3.69 ± 0.50%ID/g)和A549(0.90 ± 0.16%ID/g)。
  • 9例NSCLC患者中示踪剂摄取主要见于肾脏和脾脏,骨髓低摄取,辐射剂量在可靠范围内;肿瘤摄取与PD-L1表达TPS正相关(rs = 0.8763,P = 0.019);MPR患者SUVmax高于非MPR患者(中位2.73 vs 2.10,P = 0.036,Mann-Whitney U检验)。

临床怎么用

  • 原文结论指出该示踪剂可检测肿瘤PD-L1表达水平,并可能预测PD-1免疫联合化疗的疗效,但需在大数量病例中确认。

局限性

  • 原文结论指出需要在大数量病例中确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Programmed cell death protein-1/ligand-1 (PD-1/L1) blockade has been a breakthrough in the treatment of patients with non-small cell lung cancer (NSCLC), but there is still a lack of effective methods to screen patients. Here we report a novel 68 Ga-labeled nanobody [68 Ga]Ga-THP-APN09 for PET imaging of PD-L1 status in mouse models and a first-in-human study in NSCLC patients. METHODS: [68 Ga]Ga-THP-APN09 was prepared by site-specific radiolabeling, with no further purification. Cell uptake assays were completed in the human lung adenocarcinoma cell line A549, NSCLC cell line H1975 and human PD-L1 gene-transfected A549 cells (A549PD-L1). The imaging to image PD-L1 status and biodistribution were investigated in tumor-bearing mice of these three tumor cell types. The first-in-human clinical translational trial was registered as NCT05156515. The safety, radiation dosimetry, biodistribution, and correlations of tracer uptake with immunohistochemical staining and major pathologic response (MPR) were evaluated in NSCLC patients who underwent adjuvant immunotherapy combined with chemotherapy. RESULTS: Radiosynthesis of [68 Ga]Ga-THP-APN09 was achieved at room temperature and a pH of 6.0-6.5 in 10 min with a high radiochemical yield (> 99%) and 13.9-27.8 GBq/μmol molar activity. The results of the cell uptake study reflected variable levels of surface PD-L1 expression observed by flow cytometry in the order A549PD-L1 > H1975 > A549. In small-animal PET/CT imaging, H1975 and A549PD-L1 tumors were clearly visualized in an 8.3:1 and 2.2:1 ratios over PD-L1-negative A549 tumors. Ex vivo biodistribution studies showed that tumor uptake was consistent with the PET results, with the highest A549PD-L1 being taken up the most (8.20 ± 0.87%ID/g), followed by H1975 (3.69 ± 0.50%ID/g) and A549 (0.90 ± 0.16%ID/g). Nine resectable NSCLC patients were enrolled in the clinical study. Uptake of [68 Ga]Ga-THP-APN09 was mainly observed in the kidneys and spleen, followed by low uptake in bone marrow. The radiation dose is within a reliable range. Tumor uptake was positively correlated with PD-L1 expression TPS (rs = 0.8763, P = 0.019). Tumor uptake of [68 Ga]Ga-THP-APN09 (SUVmax) in MPR patients was higher than that in non-MPR patients (median SUVmax 2.73 vs. 2.10, P = 0.036, determined with Mann-Whitney U-test). CONCLUSION: [68 Ga]Ga-THP-APN09 has the potential to be transformed into a kit-based radiotracer for rapid, simple, one-step, room temperature radiolabeling. The tracer can detect PD-L1 expression levels in tumors, and it may make it possibility to predict the response of PD-1 immunotherapy combined with chemotherapy. Confirmation in a large number of cases is needed. TRIAL REGISTRATION: Clinical Trial (NCT05156515). Registered 12 December 2021.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Ma X, Zhou X, Hu B, et al. Preclinical evaluation and pilot clinical study of [68Ga]Ga-THP-APN09, a novel PD-L1 targeted nanobody radiotracer for rapid one-step radiolabeling and PET imaging. Eur J Nucl Med Mol Imaging. 2023. PMID: 37555904. doi:10.1007/s00259-023-06373-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。